NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAPHCILLIN (methicillin sodium) is a semi-synthetic penicillinase-resistant beta-lactam antibiotic administered by injection. It is indicated for treatment of staphylococcal infections, particularly those caused by penicillinase-producing Staphylococcus aureus. Methicillin works by inhibiting bacterial cell wall synthesis, rendering it bactericidal against susceptible gram-positive organisms.
Pre-Launch
Pre-launch stage indicates foundational team-building phase; recruitment likely focused on regulatory, medical affairs, and manufacturing roles ahead of market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STAPHCILLIN is in pre-launch phase under Bristol Myers Squibb sponsorship, meaning career opportunities are nascent and concentrated in launch readiness functions. Professionals joining now would build foundational infrastructure for a niche injectable antibiotic re-entry, with limited long-term upside unless significant clinical or market differentiation emerges.
Brand Manager
Worked on STAPHCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.